Eli Lilly and Incyte's arthritis drug baricitinib helped reduce the risk of death in hospitalised Covid-19 patients by 13 percent regardless of which other coronavirus treatment they were given, according to a large British study.

More than 8,000 patients were administered baricitinib in addition to usual care, at random, or usual care alone, as part of the so-called “Recovery” trial, scientists from the University of Oxford said on Thursday...